Peregrine Pharmaceuticals Inc. (Nasdaq: PPHM) reported positive results from a Phase II clinical trial of bavituximab for treating patients with Stage IV pancreatic cancer but TheStreet said that the results were the same as a placebo sending the stock price downy 42 cents to close at $1.69.